Also found in: Dictionary, Wikipedia.



Pharmacologic class: Thienopyridine platelet inhibitor

Therapeutic class: Antiplatelet drug

Pregnancy risk category B

FDA Box Warning

• Drug can cause significant, sometime fatal, bleeding.

• Don't use in patients with active pathological bleeding or history of transient ischemic attack or stroke (patients age 75 and older).

• Drug is generally not recommended, because of increased risk of fatal and intracranial bleeding and uncertain benefit. In high-risk situations (such as patients with diabetes or history of prior myocardial infarction, where its effect appears to be greater), its use may be considered.

• Don't start drug in patients likely to undergo urgent coronary artery bypass graft (CABG). If possible, discontinue drug at least 7 days before any surgery.

• Additional risk factors for bleeding include body weight of less than 132 lb (60 kg), propensity for bleeding, concomitant use of medications that increase bleeding risk (such as warfarin, heparin, fibrinolytics, and nonsteroidal anti-inflammatory drugs [prolonged use]). Suspect bleeding in patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures.

• If possible, manage bleeding without discontinuing drug. Discontinuing drug, particularly in first few weeks after acute coronary syndrome, increases risk of subsequent cardiovascular events.


Inhibits platelet activation and aggregation through irreversible binding of its active metabolite to the P2Y12 class of adenosine diphosphate receptors on platelets


Tablets: 5 mg, 10 mg

Indications and dosages

Reduction of rate of thrombotic cardiovascular events in patients with acute coronary syndrome who are to be managed with PCI as follows: patients with unstable angina or non-ST-elevation myocardial infarction (MI) and patients with ST-elevation MI when managed with primary or delayed PCI

Adults: Initially, 60 mg P.O. as loading dose; then, 10 mg P.O. daily (with aspirin 75 to 325 mg daily)

Dosage adjustment

• Adults weighing less than 132 lb


• Hypersensitivity to drug or its components

• Active pathological bleeding

• History of transient ischemic attack or cerebrovascular accident


Use cautiously in:

• CABG-related bleeding, patients at general risk for bleeding

• thrombotic thrombocytopenia purpura

• low body weight (less than 132 lb)

• elderly patients age 75 and older (use not recommended except in high-risk situations, such as diabetes and history of MI)

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Administer with or without food.

Be aware that premature drug discontinuation increases risk of stent thrombosis, MI, and death.

Adverse reactions

CNS: headache, dizziness, fatigue, intracranial hemorrhage

CV: hypertension, hypotension, bradycardia, peripheral edema, atrial fibrillation

EENT: epistaxis

GI: nausea, diarrhea, GI hemorrhage

Hematologic: leukopenia, bleeding, life-threatening bleeding, thrombotic thrombocytopenia purpura

Metabolic: hypercholesterolemia, hyperlipidemia

Musculoskeletal: back pain, extremity pain

Respiratory: dyspnea, cough

Skin: rash

Other: chest pain, pyrexia, newly diagnosed malignancies


Drug-drug. Nonsteroidal anti-inflammatory drugs, warfarin: increased risk of bleeding

Drug-diagnostic tests. Cholesterol, lipids: increased levels

White blood cells: decreased count

Patient monitoring

Closely monitor coagulation studies and CBC with white cell differential and watch for evidence of bleeding.

• Monitor cholesterol and lipid levels closely.

Patient teaching

• Instruct patient to take drug with or without food.

Instruct patient to immediately report to prescriber blood in stool or urine or unanticipated, prolonged, or excessive bleeding.

Instruct patient to promptly report to prescriber if fever, weakness, extreme skin paleness, purple skin patches, or neurologic changes, such as dizziness or headache, occur.

• Advise patient to notify all health care professionals that he's taking prasugrel.

• Advise patient not to take other prescription or nonprescription drugs or dietary supplements without first discussing with prescriber.

• Caution patient not to discontinue drug without first discussing with prescriber.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(pra-soo-grel) ,


(trade name)


Therapeutic: antiplatelet agents
Pharmacologic: thienopyridines
Pregnancy Category: B


Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who will be managed with PCI including patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI).Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with STEMI when managed with either primary/delayed PCI.


Acts by irreversibly binding its active metabolite to the P2Y12 class of ADP receptors on platelets; inhibiting platelet activation and aggregation.

Therapeutic effects

Decreased thrombotic events including cardiovascular death, nonfatal myocardial infarction (MI) and nonfatal stroke.


Absorption: Well absorbed following oral administration (79%), then rapidly converted to an active metabolite.
Distribution: Unknown.
Protein Binding: Active metabolite—98%.
Metabolism and Excretion: Active metabolite is metabolized to two inactive compounds; 68% excreted in the urine and 27% in feces as inactive metabolites.
Half-life: Active metabolite—7 hr (range 2–15 hr).

Time/action profile (effect on platelet function)

POwithin 1 hr2 hr5–9 days†
† Following discontinuation.


Contraindicated in: Hypersensitivity;Active pathological bleeding;History of transient ischemic attack or stroke.
Use Cautiously in: Patients about to undergo coronary artery bypass grafting (CABG) (↑ risk of bleeding; discontinue at least 7 days prior to surgery);Premature discontinuation (↑ risk of stent thrombosis, MI, and death);Body weight <60 kg, propensity to bleed, severe hepatic impairment, concurrent use of medications that ↑ the risk of bleeding (↑ risk of bleeding);Hypotension in the setting of recent coronary angiography, PCI, CABG, or other surgical procedure (suspect bleeding but do not discontinue prasugrel); Geriatric: Use in patients ≥75 yr of age generally not recommended (↑ risk of fatal/intracranial bleeding and questionable benefit, except in high-risk patients such as diabetes or prior MI); Obstetric: Use only if potential benefit to mother justifies potential risk to fetus; Lactation: Use only if potential benefit to the mother justifies potential risk to nursing infant; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness
  • fatigue
  • headache


  • cough
  • dyspnea


  • atrial fibrillation
  • bradycardia
  • hypertension
  • hypotension
  • peripheral edema


  • diarrhea
  • nausea


  • rash


  • bleeding (life-threatening)
  • thrombotic thrombocytopenic purpura (life-threatening)
  • leukopenia


  • hyperlipidemia


  • back pain
  • extremity pain


  • allergic reactions including angioedema (life-threatening)
  • fever
  • non-cardiac chest pain


Drug-Drug interaction

↑ risk of bleeding with warfarin and NSAIDs.


Aspirin 75–325 mg/daily should be taken concurrently
Oral (Adults ≥60 kg) 60 mg initially as a loading dose, then 10 mg once daily.
Oral (Adults < 60 kg) Consider maintenance dose of 5 mg once daily.


Tablets: 5 mg, 10 mg

Nursing implications

Nursing assessment

  • Assess patient for symptoms of stroke, peripheral vascular disease, or MI periodically during therapy.
  • Monitor patient for signs of thrombotic thrombocytic purpura (thrombocytopenia, microangiopathic hemolytic anemia, neurologic findings, renal dysfunction, fever). May rarely occur, even after short exposure (<2 wk). Requires prompt treatment.
  • Lab Test Considerations: Monitor bleeding time during therapy. Prolonged bleeding time, which is time- and dose-dependent, is expected.
    • Monitor CBC with differential and platelet count periodically during therapy. Thrombocytopenia and anemia may rarely occur.

Potential Nursing Diagnoses

Risk for injury (Indications,  Side Effects)


  • Discontinue prasugrel 7 days before planned surgical procedures.
    • Patients should take aspirin 75–325 mg daily with prasugrel.
  • Oral: Administer once daily without regard to food.

Patient/Family Teaching

  • Instruct patient to take medication as directed. Take missed doses as soon as possible unless almost time for next dose; do not double doses. Do not discontinue without consulting health care professional. Advise patient to read Medication Guide before taking and with each Rx refill; new information may be available.
  • Advise patient to notify health care professional promptly if fever, weakness, skin paleness, purple skin patches, yellowing of skin or eyes, chills, sore throat, neurological changes, or unusual bleeding or bruising, swelling of lips, difficulty breathing, rash, or hives occurs.
  • Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially NSAIDs.

Evaluation/Desired Outcomes

  • Prevention of stroke, MI, and vascular death in patients at risk.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Studies have shown that using the newer P2Y12 inhibitors (ie, prasugrel and ticagrelor) after PCI leads to a significant reduction in recurrent ischemic events when compared to clopidogrel.
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Therefore, the clinical value of using new types of oral antiplatelet drugs, including ticagrelor and prasugrel, and triple therapy requires further assessment using a large-scale clinical study.
Abdus Samad said that in NSTE-ACS patients in whom coronary anatomy is not known, it is not recommended to administer Prasugrel. Prasugrel is also not recommended in patient's age seventy five years or above and those with body weight of less than 60kg or history of previous intra-cranial hemorrhage, previous ischemic stroke or TIA.
Two trials of DAPT in heart-attack patients showed that prasugrel and ticagrelor were superior to clopidogrel, when used with aspirin.
Do not stop Clopidogrel or prasugrel without expert advice.
Moreover, prasugrel has been shown to be more cost-effective than clopidogrel for patients with an ACS and planned percutaneous coronary intervention.
Prasugrel, with its more potent effect, is the immediate successor to clopidogrel.
Two case reports evaluated use of prasugrel as an alternative antiplatelet agent and indicate that the arthralgia ADE may not be a thienopyridine class effect [5, 6].
Raber et al., "Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland," Heart, vol.
Patients in either of these categories metabolize enough clopidogrel into the active form to get full benefit from the drug and derive no additional efficacy benefit from switching to another P2Y12 inhibitor, such as ticagrelor or prasugrel (Effient)--drugs unaffected by metabolizer status.
Medications commonly given after placement of a stent include Clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), and aspirin.